Covered recipient · General Payments record
SANDESH JAIN
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
General Payments · PY2018–2024
$1,740.09
- Reported across 114 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $217.00 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $90.60 | 6 |
| GlaxoSmithKline, LLC. | $31.32 | 2 |
| Retrophin, Inc. | $22.94 | 2 |
| Ardelyx, Inc. | $16.83 | 1 |
| CALLIDITAS THERAPEUTICS US INC. | $14.67 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $13.77 | 1 |
| Kyowa Kirin, Inc. | $13.55 | 1 |
| ANI Pharmaceuticals, Inc. | $13.32 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $15.62 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115758551 | CMS |
| Amgen Inc. | $13.86 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117587453 | CMS |
| Amgen Inc. | $15.60 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115758560 | CMS |
| Amgen Inc. | $13.98 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117587455 | CMS |
| Amgen Inc. | $15.64 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115758568 | CMS |
| Amgen Inc. | $15.90 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117587457 | CMS |
| ANI Pharmaceuticals, Inc. | $13.32 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1091158788 | CMS |
| Ardelyx, Inc. | $16.83 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146686591 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $14.67 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141515917 | CMS |
| GlaxoSmithKline, LLC. | $15.27 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116351866 | CMS |
| GlaxoSmithKline, LLC. | $16.05 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116521838 | CMS |
| Kyowa Kirin, Inc. | $13.55 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127042469 | CMS |
| Novartis Pharmaceuticals Corporation | $13.77 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087112678 | CMS |
| Travere Therapeutics, Inc. | $12.02 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149873183 | CMS |
| Travere Therapeutics, Inc. | $10.92 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149873179 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.